Similar articles

• Parkinson's disease, melanoma, and levodopa.

  Fermaglich J, Delaney P. Fermaglich J, et al. J Neurol. 1977 Jun 13;215(3):221-4. doi: 10.1007/BF00312480. J Neurol. 1977. PMID: 69691 No abstract available.
• Impaired levodopa response in Parkinson's disease during melanoma therapy.

  Merello M, Esteguy M, Perazzo F, Leiguarda R. Merello M, et al. Clin Neuropharmacol. 1992 Feb;15(1):69-74. doi: 10.1097/00002826-199202000-00010. Clin Neuropharmacol. 1992. PMID: 1576600
• Levodopa, melanoma, and Parkinson's disease.

  Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN. Weiner WJ, et al. Neurology. 1993 Apr;43(4):674-7. doi: 10.1212/wnl.43.4.674. Neurology. 1993. PMID: 8469320 Review.
• [Melanomas and basal cell carcinomas in a patient with Parkinson disease].

  Hiraldo A, Gómez-Moyano E, Martínez S, Sanz A. Hiraldo A, et al. Actas Dermosifiliogr. 2010 Jan-Feb;101(1):95-6. Actas Dermosifiliogr. 2010. PMID: 20109402 Spanish. No abstract available.
• A Review of the Association Between Parkinson Disease and Malignant Melanoma.

  Disse M, Reich H, Lee PK, Schram SS. Disse M, et al. Dermatol Surg. 2016 Feb;42(2):141-6. doi: 10.1097/DSS.0000000000000591. Dermatol Surg. 2016. PMID: 26771684 Review.